JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Search

Pfizer

Uždarymo kaina

SektoriusSveikatos priežiūra

24.68 0.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.4

Max

24.74

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-45M

2.9B

Pardavimai

938M

15B

P/E

Sektoriaus vid.

13.106

37.003

Pelnas, tenkantis vienai akcijai

0.78

Dividendų pajamingumas

6.87

Pelno marža

19.982

Darbuotojai

81,000

EBITDA

266M

5.3B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+16.02% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

6.87%

2.25%

Kitas uždarbis

2025-11-04

Kitas dividendų mokėjimo data

2025-12-01

Kita Ex Dividend data

2025-11-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

7.1B

141B

Ankstesnė atidarymo kaina

24.64

Ankstesnė uždarymo kaina

24.68

Naujienos nuotaikos

By Acuity

44%

56%

140 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Pfizer Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-03 13:48; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Files Second Lawsuit Seeking to Block Novo Nordisk's Bid for Metsera

2025-11-03 21:11; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

2025-11-03 17:04; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera -- Update

2025-11-03 17:03; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera -- Barrons.com

2025-11-03 16:05; UTC

Įsigijimai, susijungimai, perėmimai

Metsera Calls Pfizer's Litigation Arguments 'Nonsense' and Will 'Address Them in Court' >MTSR

2025-11-03 16:04; UTC

Įsigijimai, susijungimai, perėmimai

Metsera Says Pfizer Is Trying to 'Litigate Its Way to Buying Metsera for a Lower Price Than Novo Nordisk' >MTSR

2025-11-03 16:03; UTC

Įsigijimai, susijungimai, perėmimai

Metsera Issues Statement in Response to Pfizer Litigation

2025-11-03 14:19; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera -- WSJ

2025-11-03 11:07; UTC

Rinkos pokalbiai

Novo Nordisk's Metsera Bid Shows It's No Longer Driving in The Slow Lane -- Market Talk

2025-11-03 09:49; UTC

Karštos akcijos

Stocks to Watch Monday: Berkshire Hathaway, Onsemi, Palantir -- WSJ

2025-11-02 10:30; UTC

Įsigijimai, susijungimai, perėmimai

Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk -- Heard on the Street -- WSJ

2025-10-31 22:44; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

2025-10-31 21:25; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

2025-10-31 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

2025-10-31 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

2025-10-31 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

2025-10-31 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

2025-10-31 20:46; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

2025-10-31 19:54; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

2025-10-31 19:54; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

2025-10-31 13:49; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Novo Nordisk's Move for Metsera Looks Defensive -- Market Talk

2025-10-31 12:20; UTC

Uždarbis

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings. -- Barrons.com

2025-10-30 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. -- Barrons.com

2025-10-30 16:52; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- WSJ

2025-10-30 16:52; UTC

Įsigijimai, susijungimai, perėmimai

Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ

2025-10-30 15:09; UTC

Įsigijimai, susijungimai, perėmimai

Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker. -- Barrons.com

2025-10-30 14:00; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Metsera, Pfizer Debate Superiority of Novo Bid -- Market Talk

2025-10-30 13:49; UTC

Uždarbis

Merck Stock Falls. Sales of Key Products Missed Estimates. -- Barrons.com

2025-10-30 13:44; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- 4th Update

2025-10-30 13:39; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Novo Nordisk's Pursuit of Metsera Could Be a Sore Loss For Pfizer -- Market Talk

Akcijų palyginimas

Kainos pokytis

Pfizer Prognozė

Kainos tikslas

By TipRanks

16.02% į viršų

12 mėnesių prognozė

Vidutinis 28.6 USD  16.02%

Aukščiausias 34 USD

Žemiausias 24 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pfizer kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

17 ratings

4

Pirkti

12

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

22.855 / 23.85Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

140 / 373 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat